Adrian Terek

497 posts

Adrian Terek banner
Adrian Terek

Adrian Terek

@TerekAdrian

Patient Advocate. Knowledge Dispersion. #ClinicalTrials LifeTrials - Coming Soon. Dont let the perfect become the enemy of the good

Katılım Mayıs 2020
477 Takip Edilen199 Takipçiler
Adrian Terek
Adrian Terek@TerekAdrian·
@PTarantinoMD Pd-l2 is an interesting target for an ADC. Didn't realize the protein expression levels were so low in normal tissue.
English
0
0
0
0
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
A new potent ADC on the horizon? In this phase 1 trial update, to be presented at #ESMO22, the anti-B7H3 ADC #DS7300 achieved 30% ORR (n=30/91) among patients with highly pretreated cancers (mostly prostate, SCLC & NSCLC). DXd confirms a great ADC payload. oncologypro.esmo.org/meeting-resour…
Paolo Tarantino tweet media
English
3
12
60
0
Adrian Terek
Adrian Terek@TerekAdrian·
@BrunoBockorny @BIDMChealth Rego and TAS-102 are astonishingly low bars to get over. It speaks volumes about how important this type of progress can hopefully be.
English
1
0
1
0
Bruno Bockorny MD FACP
Bruno Bockorny MD FACP@BrunoBockorny·
This is heavily pre-treated population, median of 4 prior lines. Now, compare this Regorafenib and Lonsurf... Looking forward to the phase 2 study. @BIDMChealth
Bruno Bockorny MD FACP tweet mediaBruno Bockorny MD FACP tweet media
English
1
0
2
0
Arndt Vogel
Arndt Vogel@ArndtVogel·
New #immunotherapy kids on the block for advanced #CRC? Very promising data presented #WCGCI2022 Botensilimab and Balstilimab —> Fc enhanced CTLA4/PD1 combination Compelling ORR of 24% Is there a role of liver mets for IO efficacy? @myESMO @OncoAlert
Arndt Vogel tweet media
English
1
6
29
0
Adrian Terek
Adrian Terek@TerekAdrian·
@rschilsky You don't understand. It only cures cancer when used in a cocktail of 19 other off label drugs in low doses.
English
0
0
0
0
Richard Schilsky
Richard Schilsky@rschilsky·
Have yet to see a positive trial of metformin in any cancer. This is why we do rigorous clinical research and not follow anecdotes.
English
1
3
20
0
Adrian Terek
Adrian Terek@TerekAdrian·
@Biotech2k1 I will definitely have to dig in later, this is the first I am hearing about it.
English
1
0
2
0
Biotech2k
Biotech2k@Biotech2k1·
@TerekAdrian It is awesome isn't it. The break the CAR into 2 parts so they can administer the linker like and antibody then it binds to the universal CAR on these NK cells.
English
2
0
1
0
Biotech2k
Biotech2k@Biotech2k1·
Looking at $IPSC and its incredible technology. They introduce the key parts of the technology that go together to provide a multi functional platform for CAR-T and CAR-NK cells unlike I have never seen before.
English
2
3
34
0
Adrian Terek
Adrian Terek@TerekAdrian·
@Biotech2k1 What the heck did I just read?! This is a wildly interesting approach.
English
1
0
1
0
Biotech2k
Biotech2k@Biotech2k1·
The second technology was the invention of a universal CAR. This CAR targets a unique protein they created. This technology allows 1 CAR-NK cell to work with any antigen as you can just dose the antigen binders and have one CAR-NK cell work with them all.
Biotech2k tweet media
English
2
0
6
0
Adrian Terek
Adrian Terek@TerekAdrian·
@TreeBanker @ThanksCancer I agree completely that it's difficult. Only being around someone when it's fun and easy is the definition of a fair weather friend.
English
0
0
1
0
Dan @ Dan Can't Cook ______
Dan @ Dan Can't Cook ______@TreeBanker·
@TerekAdrian @ThanksCancer I’d agree if it were not for the fact that so many people are dealing with, or have dealt with the worst aspects of #CANCER … I’m sure some people simply can’t face the idea of a friend dying from it, and retreat in horror
English
1
1
1
0
Dan @ Dan Can't Cook ______
Dan @ Dan Can't Cook ______@TreeBanker·
Dear @ThanksCancer … What’s the best way to deal with friends who “ghost” us (pardon the pun) while we’re going through treatment. Then come back like nothing happened when they realize we’re not going to die?
English
32
3
102
0
Adrian Terek
Adrian Terek@TerekAdrian·
@Simple_Trials This was my first time attending ASCO in person. I thought it was a research meeting, but it felt more like a trade show with research on the side.
English
0
0
0
0
Adrian Terek retweetledi
Mark Lewis, MD, FASCO
Mark Lewis, MD, FASCO@marklewismd·
A standard metric after therapeutic trials should be the responses to the question: “would you — the oncologist — recommend this treatment for you or your family if affected by this disease?” Patients are the ultimate stakeholders because it’s their lives on the line! #ASCO22
English
5
12
104
0

Keşfet

@PTarantinoMD @VanMorrisMD @jonathanloree @aparna1024 @NiuSanford @KrishanJethwa @sepideh_gholami @AGangiMD